Nifedipin Retard Terapia (Nifedipine)

Nifedipine, the active ingredient in Nifedipin Retard Terapia, is a calcium channel blocker presented as an extended‑release oral tablet for oral use. It treats hypertension, chronic stable angina, and Raynaud's phenomenon in adult patients.

GNH USA supplies Nifedipin Retard Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine is used to manage conditions related to vascular tone and myocardial oxygen demand.

Hypertension: lowers systemic blood pressure by arterial vasodilation. Chronic stable angina: reduces frequency of angina attacks by improving coronary blood flow. Raynaud's phenomenon: alleviates peripheral vasospasm and diminishes attack severity.

Nifedipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and reddening of the skin. - Peripheral edema: swelling of ankles or lower legs.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

Before initiating therapy, clinicians should consider several safety measures. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Abrupt discontinuation: taper dose to prevent rebound hypertension. - Hepatic impairment: use with caution; dose adjustment may be needed. - Heart failure: monitor for worsening symptoms. - Grapefruit juice: avoid as it can increase plasma levels. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nifedipine can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nifedipine concentrations. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe hypotension. - Concurrent antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause excessive blood pressure drop.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.